0
Détail d'une collection
|
|
Documents disponibles dans la collection (3)
Ajouter le résultat dans votre panier Affiner la rechercheCardiovascular mortality and exposure to airborne fine particulate matter and cigarette smoke / C. Arden Pope (2009)
Titre : Cardiovascular mortality and exposure to airborne fine particulate matter and cigarette smoke : shape of the exposure-response relationship Type de document : texte imprimé Auteurs : C. Arden Pope, Auteur ; Richard T. Burnett, Auteur ; Daniel Krewski, Auteur ; Michael Jerrett, Auteur Editeur : Lippincott Williams & Wilkins Année de publication : 2009 Collection : Circulation, ISSN 0009-7322 num. 120 Importance : p. 941-947 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] tabagisme:effet sur l'environnement:pollution
[TABAC] tabagisme:pathologie:pathologie cardio-vasculaire
[TABAC] tabagisme:tabagisme passif:tabagisme environnementalIndex. décimale : TA 7.4.2.2 chez l'adulte Résumé : ACKGROUND:
Fine particulate matter exposure from both ambient air pollution and secondhand cigarette smoke has been associated with larger risks of cardiovascular mortality than would be expected on the basis of linear extrapolations of the relative risks from active smoking. This study directly assessed the shape of the exposure-response relationship between cardiovascular mortality and fine particulates from cigarette smoke and ambient air pollution.
METHODS AND RESULTS:
Prospective cohort data for >1 million adults were collected by the American Cancer Society as part of the Cancer Prevention Study II in 1982. Cox proportional hazards regression models that included variables for increments of cigarette smoking and variables to control for education, marital status, body mass, alcohol consumption, occupational exposures, and diet were used to describe the mortality experience of the cohort. Adjusted relative risks of mortality were plotted against estimated average daily dose of fine particulate matter from cigarette smoke along with comparison estimates for secondhand cigarette smoke and air pollution. There were substantially increased cardiovascular mortality risks at very low levels of active cigarette smoking and smaller but significant excess risks even at the much lower exposure levels associated with secondhand cigarette smoke and ambient air pollution.
CONCLUSIONS:
Relatively low levels of fine particulate exposure from either air pollution or secondhand cigarette smoke are sufficient to induce adverse biological responses increasing the risk of cardiovascular disease mortality. The exposure-response relationship between cardiovascular disease mortality and fine particulate matter is relatively steep at low levels of exposure and flattens out at higher exposures.En ligne : https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.109.857888?url_ver=Z [...] Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8057 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effect of the italian smoking ban on population rates of acute coronary events Type de document : texte imprimé Auteurs : Giulia Cesaroni, Auteur ; Francesco Forastiere, Auteur ; Nera Agabiti, Auteur ; Pasquale Valente, Auteur Editeur : Lippincott Williams & Wilkins Année de publication : 2010 Collection : Circulation, ISSN 0009-7322 num. 117 Importance : p.1183-1188 Présentation : tab. Langues : Anglais (eng) Catégories : [DIVERS] géographie:Europe:Europe méridionale:Italie
[TABAC] étude
[TABAC] législation:milieu réglementé:lieu public
[TABAC] tabagisme:pathologie:pathologie cardio-vasculaire
[TABAC] tabagisme:tabagisme passifIndex. décimale : TA 9.3.6.1 Lieux publics Résumé : ackground— Several countries in the world have not yet prohibited smoking in public places. Few studies have been conducted on the effects of smoking bans on cardiac health. We evaluated changes in the frequency of acute coronary events in Rome, Italy, after the introduction of legislation that banned smoking in all indoor public places in January 2005.
Methods and Results— We analyzed acute coronary events (out-of-hospital deaths and hospital admissions) between 2000 and 2005 in city residents 35 to 84 years of age. We computed annual standardized rates and estimated rate ratios by comparing the data from prelegislation (2000–2004) and postlegislation (2005) periods. We took into account several time-related potential confounders, including particulate matter (PM10) air pollution, temperature, influenza epidemics, time trends, and total hospitalization rates. The reduction in acute coronary events was statistically significant in 35- to 64-year-olds (11.2%, 95% CI 6.9% to 15.3%) and in 65- to 74-year-olds (7.9%, 95% CI 3.4% to 12.2%) after the smoking ban. No evidence was found of an effect among the very elderly. The reduction tended to be greater in men and among lower socioeconomic groups.
Conclusions— We found a statistically significant reduction in acute coronary events in the adult population after the smoking ban. The size of the effect was consistent with the pollution reduction observed in indoor public places and with the known health effects of passive smoking. The results affirm that public interventions that prohibit smoking can have enormous public health implicationsPermalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8088 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005637 TA 9.3.6.1 CES E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease : a randomized trial Type de document : texte imprimé Auteurs : Nancy A. Rigotti, Auteur ; Andrew L. Pipe, Auteur ; Neal L. Benowitz, Auteur ; Carmen Arteaga, Auteur Editeur : Lippincott Williams & Wilkins Année de publication : 2010 Collection : Circulation, ISSN 0009-7322 num. 121:2 Importance : p. 221-229 Langues : Anglais (eng) Catégories : [TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
[TABAC] tabagisme:pathologie:pathologie cardio-vasculaireIndex. décimale : TA 6.2.3.2 Autres produits Résumé : BACKGROUND:
Smoking cessation is a key component of secondary cardiovascular disease prevention. Varenicline, a partial alpha4beta2 nicotinic acetylcholine receptor agonist, is effective for smoking cessation in healthy smokers, but its efficacy and safety in smokers with cardiovascular disease are unknown.
METHODS AND RESULTS:
A multicenter, randomized, double-blind, placebo-controlled trial compared the efficacy and safety of varenicline with placebo for smoking cessation in 714 smokers with stable cardiovascular disease. Participants received varenicline (1 mg twice daily) or placebo, along with smoking-cessation counseling, for 12 weeks. Follow-up lasted 52 weeks. The primary end point was carbon monoxide-confirmed continuous abstinence rate for weeks 9 through 12 (last 4 weeks of treatment). The continuous abstinence rate was higher for varenicline than placebo during weeks 9 through 12 (47.0% versus 13.9%; odds ratio, 6.11; 95% confidence interval [CI], 4.18 to 8.93) and weeks 9 through 52 (19.2% versus 7.2%; odds ratio, 3.14; 95% CI, 1.93 to 5.11). The varenicline and placebo groups did not differ significantly in cardiovascular mortality (0.3% versus 0.6%; difference, -0.3%; 95% CI, -1.3 to 0.7), all-cause mortality (0.6% versus 1.4%; difference, -0.8%; 95% CI, -2.3 to 0.6), cardiovascular events (7.1% versus 5.7%; difference, 1.4%; 95% CI, -2.3 to 5.0), or serious adverse events (6.5% and 6.0%; difference, 0.5%; 95% CI, -3.1 to 4.1). As a result of adverse events, 9.6% of varenicline and 4.3% of placebo participants discontinued study drug.
CONCLUSIONS:
Varenicline is effective for smoking cessation in smokers with cardiovascular disease. It was well tolerated and did not increase cardiovascular events or mortality; however, trial size and duration limit definitive conclusions about safety.En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096941/ Format de la ressource électronique : PDF, HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8369 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
